Australia markets open in 1 hour 24 minutes

    -39.80 (-0.50%)

    +0.0018 (+0.27%)
  • ASX 200

    -37.40 (-0.49%)
  • OIL

    -0.05 (-0.06%)
  • GOLD

    -0.90 (-0.04%)
  • Bitcoin AUD

    +946.26 (+0.93%)
  • CMC Crypto 200

    -27.19 (-1.87%)

Danaher Corporation (NYSE:DHR) Q1 2024 Earnings Call Transcript

Danaher Corporation (NYSE:DHR) Q1 2024 Earnings Call Transcript April 23, 2024

Danaher Corporation misses on earnings expectations. Reported EPS is $1.45 EPS, expectations were $1.72.

Operator: Hello. My name is Todd, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2024 Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] I will now turn the call over to Mr. John Bedford, Vice President of Investor Relations. Mr. Bedford, you may begin your conference.

John Bedford: Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, the slide presentation supplementing today's call and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call and a note containing details of historical and anticipated future financial performance are all available on the Investors section of our website, under the heading, Quarterly Earnings. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call.


A replay of this call will also be available until May 7, 2024. During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to results from continuing operations and relate to the first quarter of 2024 and all references to period-to-period increases or decreases in financial metrics are year-over-year. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals or are available only in certain markets.

During the call, we will make forward-looking statements within the meaning of the federal securities laws including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements, except as required by law. With that, I'd like to turn the call over to Rainer.

Rainer Blair: Thanks very much, John, and good morning, everyone. We appreciate you joining us on the call today. We're off to a good start in 2024 with our team delivering better than expected revenue, earnings and cash flow. We were especially pleased to see improving order trends in our bioprocessing business and believe we continue to gain market share at Cepheid in the quarter. Now this better than expected start to the year, paired with improving funnel and order trends further supports our full year outlook, which is unchanged from our previous guidance. Our first quarter results also reflect the unique positioning of Danaher's portfolio today. Our businesses are well positioned in attractive end markets, all underpinned by long-term secular growth drivers with high margin, high recurring revenue business models.

Our strong free cash flow generation also positions us well to further enhance our portfolio going forward. Now it's not just the portfolio that differentiates Danaher. It's how we run the business using the Danaher Business System, or DBS. Our team's commitment to executing with DBS enables us to deliver impactful new innovations to our customers and drive meaningful process improvements in our businesses, both of which are helping position Danaher for sustainable long-term performance. Now a prime example of the power of DBS is the CEO Kaizen, we kicked off just two weeks ago. During this pivotal annual event, our most senior leaders operating company presidents and thousands of associates come together to address some of our most significant opportunities for material and sustained improvements in our businesses.

In fact, just last week, I rolled up my fleet at one of our filtration manufacturing facilities in Pensacola, Florida to focus on increasing manufacturing throughput and reducing lead times. CBS is our culture, and this year's CEO Kaizen underscores how our commitment to continuous improvement at all levels of the organization can contribute to a better customer experience, and lasting competitive advantage across our businesses. So with that, let's take a closer look at our first quarter 2024 results. Sales were $5.8 billion in the first quarter and core revenue declined 4%. Geographically, core revenues in developed markets were down slightly with broad-based strength across diagnostics, offset by declines in biotechnology. High growth markets declined low double-digits, including a high-teens decline in China where the economic landscape remains challenging.

Our gross profit margin for the first quarter was 60%. Our adjusted operating profit margin of 30.1% was down 170 basis points as the favorable impact of cost savings initiatives was more than offset by lower volume. Adjusted diluted net earnings per common share were $1.92. We generated $1.4 billion of free cash flow in the quarter resulting in a free cash flow to net income conversion ratio of more than 130%. So now let's take a closer look at our results across the portfolio and give you some color on what we're seeing in our end markets today. Core revenue in our Biotechnology segment declined 17%, with Bioprocessing down high-teens, and Discovery and Medical down approximately 20%. In Bioprocessing, we had a modestly better than expected start to the year.

Orders increased mid-single digits sequentially from the fourth quarter of 2023 and our book-to-bill ratio increased to approximately 0.95. Now this is particularly encouraging as we typically see a seasonal order decline between the fourth quarter and the first quarter. In North America and Europe, our larger customers are making steady progress working through their excess inventory with many returning to their regular order patterns. We expect inventory levels that these customers have largely normalized exiting the second quarter. We are also encouraged with improvements in the overall funding environment, while we don't expect these improvements to impact order activity in the near term, it is a positive indicator for the long-term health of the Bioprocessing market.

Now in China, demand and underlying activity levels remain weak as customers are continuing to conserve capital and prioritize programs. Now for the full year 2024, there is no change to our expectation of a low-single digit core revenue decline in our Bioprocessing business. And there's also no change to our assumption of a gradual improvement through the year to a core revenue growth rate of high-single digits or better as we exit 2024. Despite near-term headwinds, robust underlying market trends reinforce our confidence in the health and long-term growth profile of the biologics market. Underlying demand for biologic medicines is projected to grow at a high-single digit or better rate again for the full year 2024. There is also an increasing number of therapies advancing through the development pipeline and reaching the market.

A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens.
A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens.

In setback, the number of new FDA approvals for biologic (ph) and genomic medicines grew more than 50% last year. These positive trends reinforce our conviction in the significant opportunity ahead in the high-single digit long-term core revenue growth trajectory for our leading bioprocessing franchise. Now we continue to make substantial investments in innovation geared towards helping our customers reduce the time and cost of biologic drug production. Cytiva's recently released Xcellerex magnetic mixing system is a great example of how we are improving productivity and reducing risk in biologic drug manufacturing. This innovative single-use cell culture media mixer enables faster and more consistent mixing and specifically designed to prevent leaks common with other large-scale mixing systems that can lead to complete batch loss.

This also marks another significant milestone for Cytiva as the first new product release to be developed, leveraging the capabilities of our recently combined Pall Life Sciences and Cytiva R&D team. Now let's turn to our Life Science segment, where core revenue decreased by 3%. Core revenue in our Life Sciences instruments businesses collectively declined mid-single digits with trends in the first quarter, largely consistent with what we saw in the second half of 2023. In developed markets, pharma and biotech activity remained stable, but at lower levels of demand. We did see improving funnel activity as the quarter progressed, but this increased activity has not yet translated to orders. Academic and applied markets performed comparatively better, particularly for our more advanced instrumentation.

In China, the [indiscernible] were driven by difficult comparisons as a result of the prior year stimulus programs and lower demand as a result of weaker underlying activity levels. Our genomics consumables business delivered low-single digit core revenue growth in the quarter, double-digit growth across plasmids and protein was partially offset by declines in next-generation sequencing and gene writing and editing solutions. While current end market conditions remain challenging, our Life Sciences businesses are well positioned for the long term. A combination of investments in innovation and strategic acquisitions over the last several years has increased our exposure to attractive end markets in Life Sciences and accelerated our growth trajectory.

Additionally, with high-margin recurring revenue now comprising more than 60% of the segment, we see opportunities for future margin improvement. Let's move to our Diagnostics segment, where our core revenue increased by 7.5%. Our clinical diagnostics businesses collectively delivered mid-single digit core revenue growth. Beckman Coulter Diagnostics was up mid-single digits for the fifth consecutive quarter with solid growth in both instruments and consumables. Segment's recent strong performance is a direct result of leveraging the Danaher Business System to improve both innovation and commercial execution, new product introductions over the last few years, including the DxI 9000 immunoassay analyzer, the DxC 500 chemistry analyzer and the DxA 5000 Fit automation system have expanded our offerings and improved Beckman's competitive positioning.

We're also seeing better win and retention rates across the portfolio. At Leica Biosystems, the Aperio GT450 DX digital pathology slide scanner recently received FDA 510(k) clearance. Now with this significant milestone, the GT450 can now be more widely used in pathology labs, moving digital pathology one step closer to becoming the standard of care for clinicians. Digital pathology provides many benefits to clinicians, including improving analytical capabilities through predictive algorithms, enhancing slide imaging and increasing productivity. All of which help provide a more accurate and timely diagnosis of patients. So this clearance also highlights how proprietary innovation is driving long-term core growth at Leica. In Molecular Diagnostics, Cepheid's core revenue increased double-digits.

And as I mentioned earlier, we believe the team continued to gain market share during the quarter. Cepheid's respiratory revenue of approximately $675 million in the quarter exceeded our expectation of $575 million, driven by both higher volumes and a favorable mix of our four-in-one test for COVID-19, Flu A, Flu B and RSV. Now based on current global trends and respiratory infection rates, we continue to expect respiratory revenue of approximately $1.6 billion for the full year of 2024. Cepheid's installed base continued to grow in the quarter to over 55,000 systems globally, a more than three-fold increase since 2019. The team's thoughtful approach to placing systems that customers with clinical use cases beyond the pandemic has continued to drive increased menu adoption and utilization.

We're seeing this today through growth rates in assays such as Group A, stress and sexual health, which were each up more than 40% in the first quarter. We're also seeing customers return to testing protocols that were suspended during the pandemic, which helped drive mid-teens growth in hospital acquired infection assays. Now in January, Cepheid received expanded FDA clearance with a CLIA waiver for the expert Xpress MVP test, which is the latest addition to our growing women's health portfolio. With the addition of the CLIA waiver, Cepheid's customers can now provide critical testing in care settings that are more easily accessible to patients, like a physician's office or a local clinic, reducing the need for multiple office visits and significantly narrowing the tested treatment gaps often associated with therapeutic failure.

This is a great example of how bringing accurate, easy-to-use molecular testing closer to patients is improving treatment outcomes and driving long-term growth at Cepheid. So now let's briefly look ahead at expectations for the second quarter and the full year 2024. In the second quarter, we expect core revenue to decline in the mid-single digit percent range. Additionally, we expect a second quarter adjusted operating profit margin of approximately 26%. For the full year 2024, there is no change to our previous guidance. As a reminder, we anticipate a core revenue decline in the low-single digit percent range and a full year adjusted operating profit margin of approximately 29%. So to wrap up, we're pleased to deliver first quarter results ahead of our expectations and look forward to building on this momentum as we move through the year.

Our team's commitment to innovating and executing with DBS is driving meaningful improvements in our businesses and enabling us to deliver more breakthrough solutions to our customers. So there's a bright future ahead for Danaher. The transformation in our portfolio paired with our organic growth investments has created a lineup of outstanding franchises that are all well positioned in highly attractive end markets. We are a focused Life Science and diagnostics leader positioned for higher long-term growth, expanded margins and stronger cash flow. So we believe this unique combination of our incredibly talented team, the strength and differentiation of our portfolio, and leading financial profile provides us with a strong foundation to create sustainable, long-term shareholder value.

And so with that, I'll turn the call back over to John.

John Bedford: Thank you, Rainer. That concludes our formal comments. Operator, we're now ready for questions.

See also

25 States With the Highest Gas Prices and

30 Least Developed Countries in Africa in 2024.

To continue reading the Q&A session, please click here.